Secrecy on cost of publicly funded hep C treatment.
作者信息
Webster Paul
机构信息
Toronto, Ontario.
出版信息
CMAJ. 2017 Apr 24;189(16):E617-E618. doi: 10.1503/cmaj.1095412.
Abstract
摘要
相似文献
1
Secrecy on cost of publicly funded hep C treatment.
CMAJ. 2017 Apr 24;189(16):E617-E618. doi: 10.1503/cmaj.1095412.
2
Reducing the price of new hepatitis C drugs in the Tuscany region of Italy.
BMJ. 2015 Jun 24;350:h3363. doi: 10.1136/bmj.h3363.
3
Hepatitis C drug affordability.
Lancet Glob Health. 2015 Feb;3(2):e73-4. doi: 10.1016/S2214-109X(14)70365-1.
4
Coverage for hepatitis C drugs in Medicare Part D.
Am J Manag Care. 2016 May;22(6 Spec No.):SP220-6.
5
Saskatchewan agrees to cover new HCV and HIV drugs.
Can HIV AIDS Policy Law Rev. 2003 Aug;8(2):28.
6
Hepatitis C: how has France limited the expenses related to new treatments?
Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):655-657. doi: 10.1080/14737167.2016.1247696. Epub 2016 Oct 27.
7
Disparity in market prices for hepatitis C virus direct-acting drugs.
Lancet Glob Health. 2015 Nov;3(11):e676-7. doi: 10.1016/S2214-109X(15)00156-4.
8
Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness?
Eur J Health Econ. 2015 May;16(4):341-5. doi: 10.1007/s10198-014-0653-x.
9
Hepatitis C treatment in Guatemala: the struggle for access.
Lancet. 2018 Jul 28;392(10144):269-270. doi: 10.1016/S0140-6736(18)31213-3.
10
How does complementary private prescription drug insurance coverage affect seniors' use of publicly funded medications?
Health Policy. 2013 May;110(2-3):147-55. doi: 10.1016/j.healthpol.2013.02.010. Epub 2013 Mar 19.
引用本文的文献
1
The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges?
Can Liver J. 2018 Jul 17;1(2):4-13. doi: 10.3138/canlivj.1.2.003. eCollection 2018 Spring.
2
Can we afford not to screen and treat hepatitis C virus infection in Canada?
Can Liver J. 2018 Jul 17;1(2):51-65. doi: 10.3138/canlivj.1.2.005. eCollection 2018 Spring.
Zotero 插件